Repeated Neutron delays undermine the premium on Rocket Lab stock when execution keeps slipping. The company does not live or die by Neutron, but 50x sales was unjustified; even at 26x 2027 sales, a legitimate price suggests another 50% decline. x.com  x.com 

Rocket Lab's fundamentals do not yet justify buying, even after a 55% drop took it to around its 200-day moving average. It still lacks positive earnings, net income and growing free cash flow. The upside could be significant if the business executes over the next few years, but more proof of profitability is needed first; it stays on the watch list. x.com  x.com 

Rocket Lab's bounce has room to run to $65 after buyers returned following shipment of Neutron's second stage to its Virginia launch site. A break above $65 before November 9 results remains the real test. x.com 

Rocket Lab's delayed Neutron first flight pushes out a key part of its planned launch capacity. Flight one has moved to 2027, at least 1.5 years later than the previously indicated timing; the lack of clearer guidance is frustrating. The stock could fall 50% if it breaks key support, though that downside is conditional. x.com  x.com  x.com 

Rocket Lab's only 'moat' was Neutron, and its reported launch delay now amounts to cancellation for the investment case. The quoted report puts its inaugural launch in 2027; $2.99 is floated as a possible share price. x.com 

Rocket Lab's existing Space Systems business makes Neutron upside optionality rather than the whole investment case. Space Systems supplied $189.5M, about 81% of Q2's record $234M revenue, alongside Electron launches, defense work, satellite manufacturing and components. Delaying Neutron's first launch to 2027 hurts a major catalyst and raises execution questions, but rushing a rocket failure would be costlier. x.com 

Rocket Lab could face a difficult 9-12 months because much of the space industry's future is already priced into equity valuations, even as its business and backlog grow. A monthly close below the $61 21-month EMA would raise the risk that the uptrend has ended and shift attention toward $35-45 for a better long-term entry; holding $61 preserves a more constructive reading. The company could still trade considerably higher over a longer horizon. x.com 

Rocket Lab's government awards and backlog look priced in, while the costs of Neutron do not. Its space-beta monopoly has ended with SpaceX's listing, and it needs to max out R&D to accelerate Neutron before its maiden flight. A brand-new rocket, a new methalox engine and a new launch site burning more money mean weak earnings the market has apparently not priced. x.com  x.com 

Good SpaceX earnings could help Rocket Lab lead the new-space sector higher with a rally as violent as its capitulation. Rocket Lab is the sector leader outside SpaceX; its RSI is extremely oversold, the lower Bollinger band is overstretched and MACD's negative divergence is subsiding. Three upside gaps lie at $55.25-59.18, $64.22-65.71 and $73.11-74.76. The highest should fill before year-end, though the exact date is hard to predict. x.com  x.com 

Rocket Lab's price bets on the most optimistic version of its results a decade out while it is still losing money, so the market is pricing a story rather than the company. Narrative now earns a premium and earnings do not, as with IonQ and AI-server-labeled Dell and HPE, and one quarterly miss means exit. This can last a long time in liquid, risk-on markets, as 1999 dot-coms and 2021 SPACs showed, so a drop is not imminent; buyers now are buying how long sentiment lasts. x.com